The development of bioreactor processes for cGMP monoclonal antibody (mAb) manufacturing requires reliable, accurate, and timely in-process analytical data to guide process development decisions. The measurement of IgG expression level or titer is a key upstream process output that can present challenges for the rapid and systematic optimization of robust, scalable process. This study compares Protein A HPLC with the Roche Cedex Bio instrument for profiling the expression of multiple antibody products generated from CHO cell bioreactor culture. Considerations of comparative instrument performance, accuracy, economics, and versatility are presented in the context of accelerating development timelines from bench scale development to manufacturing clinical antibody supply. Learn More